Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

it received a Staff Determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Ma July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

16:52 EST Biodexa Pharmaceuticals (BDRX ... and streamline your search for investment opportunities using Tipranks' Stock Screener Published first on TheFly – the ultimate source for real ...

Biodexa has previously received Orphan Drug ... In premarket trading Monday, the stock is up by 113.2% at $8.57. The views and opinions expressed herein are the views and opinions of the author ...

Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...

September 26, 2024 Biodexa Pharmaceuticals PLC (Biodexa or the Company) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an ...